Looking and the current market scenario, many companies are outsourcing the manufacture of their highly potent compounds for various reasons, mainly marketing. The escalation in the High Potent drug market is subjected to a variety of aspects such as the diversification of pharmaceutical manufacturers towards precision medicines such as HPAPI, increasing demand for oncology drugs & antibody-drug conjugates, and advancements in HPAPI manufacturing technologies.
We are delighted to announce our 8th Annual MarketsandMarkets High Potent Medicines Conference, scheduled to be on 24th -26th May 2023, in Italy. This conference will evidence the presence of some great minds in the Medical and Pharmaceutical industry bringing you the solutions to the challenges faced in advanced High Potent Medicines. Grab the opportunity to interact with them, 10+ hours of dedicated networking for two days in a row and meet your potential targets to create target revenue.
Process Design Containment, Jacobs
Senior Process Engineer, Exyte
Sales Director, FPS
Director, HPAPI Services
President, CEO, Affygility Soultions, USA
Global Director Containment & Micronization, DEC Group
Siegfried, Head, Drug Product Development
Operations Director, Pharma & Lab Division, Hosokawa Alpine AG
EHS Director, BSP Pharmaceuticals, Italy
Head, Operations, Aenova Group
Senior Occupational Toxicologist, SafeBridge
Occupational Hygiene Manager, SafeBridge
R&D Director, MOEHS Fine Chemicals
Process Chemist, MOEHS Fine Chemicals
Validation Expert, Novartis
Subject Matter Expert CMO, Ferring Pharmaceuticals
Engineering Director, Pharmaprocess
Director, Pharmaceutical Development, Clovis Oncology
NPI Program Manager, AbbVie
EHS & LPA Supervisor, AbbVie
Director, Scientific Affairs, PCI Pharma Services, UK
Duo Milan Porta Nuova, Via Gerolamo Cardano, 1, 20124 Milano MI, Italy.